We were incorporated in California in 1990 and commenced operations in 1992. These limitations include: • Limited versatility and precision. We believe our current technologies and our future innovations can help to achieve this. Continue to innovate through clinical development and collaboration. The CyberKnife platform maximizes patient comfort. InTempo Adaptive Imaging System. Key capabilities of these options are as follows: TomoDirect Mode. TomoDirect is standard on the TomoTherapy HDA model and Radixact X7 and X9 models. Treatment delivery is quickly completed for each beam angle. It can manage users and privileges to control patient data access. Outside the United States, we market to customers directly and through distributors. In June 2016, we received 510(k) clearance for the Radixact Treatment Delivery Platform. Pre‑market approval (PMA) pathway. After a device is placed on the market, numerous regulatory requirements apply. Such data will be made available by the government on a publicly searchable website. We are also subject to federal and state physician self‑referral laws. Both the scope and exceptions for such laws vary from state to state. Additionally, our products are subject to regulations in China. 8226; We depend on key employees, the loss of whom would adversely affect our business. As of June 30, 2021, we had an accumulated deficit of $488.0 million. In the event we fail to achieve profitability, our stock price could decline. We have been, and anticipate in the future being subject to such 40 inspections. We depend on key employees, the loss of whom would adversely affect our business. We also expect that other participants will enter the field. Our liquidity could be adversely impacted by adverse conditions in the financial markets. Either process can be expensive, lengthy and unpredictable. 56 Laws and ethical rules governing interactions with healthcare providers.
